Key Takeaways
Genetic testing company Natera Inc. (NASDAQ:NTRA) reported first-quarter revenue of $697 million, a 39 percent year-over-year increase that surpassed analyst expectations, but its stock fell as investors reacted to a wider-than-expected loss and the company’s high valuation.
"We had an outstanding first quarter, reaching over one million units processed in a single quarter for the first time and delivering strong growth across all areas," Steve Chapman, chief executive officer of Natera, said in a statement.
The company's performance shows a sharp contrast between its top and bottom lines. While revenue beat the consensus estimate of approximately $614 million by over 13 percent, its adjusted loss of $0.56 per share was wider than the anticipated $0.53 loss. Test volumes reached 1,013,600, a company record, driven by a 55 percent annual increase in clinical oncology tests.
The negative stock reaction, despite strong sales and increased full-year guidance, highlights investor sensitivity around Natera's valuation, which stands at 10 to 11 times forward revenue. The company holds a near-monopoly in the minimal residual disease (MRD) testing market with its Signatera product, an opportunity that Leerink Partners analyst Puneet Souda estimates is only 6 percent penetrated out of a $20 billion domestic market. Competitors in the space include Guardant Health and Tempus AI.
Natera raised its full-year 2026 revenue guidance by about $120 million and lifted its gross margin outlook to 65 percent. The updated forecast reflects improved pricing and reimbursement for its tests.
The results signal that Natera's growth trajectory in the underpenetrated MRD market remains strong, though profitability remains a key focus for investors. The next major catalyst will be a regulatory decision in Japan for its Signatera colorectal cancer test, expected in the second quarter of 2026, which management suggests could double the test's addressable market for that cancer type.
This article is for informational purposes only and does not constitute investment advice.
